Plasma Interleukin-5 Levels Are Related to Antibodies Binding to Oxidized Low-Density Lipoprotein and to Decreased Subclinical Atherosclerosis

Journal of the American College of Cardiology

Volumn 52, Issue 17, 2008, Pages 1370-1378

  Sämpi, Maritta ^a   Ukkola, Olavi ^a   Päivänsalo, Markku ^a   Kesäniemi, Y Antero ^a   Binder, Christoph J ^b   Hörkkö, Sohvi ^a  

^a UNIVERSITY OF OULU   (Finland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

antibody; atherosclerosis; interleukin 5; oxidized low density lipoprotein

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 5; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ANTIBODY TITER; ANTIGEN BINDING; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; COMMON CAROTID ARTERY; CONTROLLED STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERNAL CAROTID ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANIMALS; AUTOANTIBODIES; CAROTID ARTERY DISEASES; CAROTID ARTERY, INTERNAL; FEMALE; FINLAND; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN-5; LIPOPROTEINS, LDL; MALE; MICE; MIDDLE AGED; TUNICA INTIMA; TUNICA MEDIA;

EID: 53449097966     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.06.047     Document Type: Article

References (44)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
2. Binder C.J., Chang M.K., Shaw P.X., et al. Innate and acquired immunity in atherogenesis. Nat Med 8 (2002) 1218-1226
3. Hansson G.K., and Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6 (2006) 508-519
4. von der Thusen J.H., Kuiper J., van Berkel T.J., et al. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 55 (2003) 133-166
5. Tedgui A., and Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86 (2006) 515-581
6. Hörkkö S., Binder C.J., Shaw P.X., et al. Immunological responses to oxidized LDL. Free Radic Biol Med 28 (2000) 1771-1779
7. Hulthe J., Bokemark L., and Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21 (2001) 101-107
8. Karvonen J., Päivänsalo M., Kesäniemi Y.A., et al. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108 (2003) 2107-2112
9. Tsimikas S., Brilakis E.S., Lennon R.J., et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48 (2007) 425-433
10. Fukumoto M., Shoji T., Emoto M., et al. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 20 (2000) 703-707
11. Palinski W., Hörkkö S., Miller E., et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 98 (1996) 800-814
12. Binder C.J., Shaw P.X., Chang M.K., et al. The role of natural antibodies in atherogenesis. J Lipid Res 46 (2005) 1353-1363
13. Chang M.K., Bergmark C., Laurila A., et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A 96 (1999) 6353-6358
14. Hörkkö S., Bird D.A., Miller E., et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103 (1999) 117-128
15. Shaw P.X., Hörkkö S., Chang M.K., et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105 (2000) 1731-1740
16. Binder C.J., Hörkkö S., Dewan A., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9 (2003) 736-743
17. Palinski W., Miller E., and Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 92 (1995) 821-825
18. Freigang S., Hörkkö S., Miller E., et al. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 18 (1998) 1972-1982
19. Binder C.J., Hartvigsen K., Chang M.K., et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 114 (2004) 427-437
20. Ameli S., Hultgardh-Nilsson A., Regnstrom J., et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16 (1996) 1074-1079
21. Zhou X., Caligiuri G., Hamsten A., et al. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 108-114
22. George J., Afek A., Gilburd B., et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138 (1998) 147-152
23. Miller A.M., Xu D., Asquith D.L., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 205 (2008) 339-346
24. Takatsu K. Interleukin 5 and B cell differentiation. Cytokine Growth Factor Rev 9 (1998) 25-35
25. Päivänsalo M., Rantala A., Kauma H., et al. Prevalence of carotid atherosclerosis in middle-aged hypertensive and control subjects. A cross-sectional systematic study with duplex ultrasound. J Hypertens 14 (1996) 1433-1439
26. Kiema T.R., Kauma H., Rantala A.O., et al. Variation at the angiotensin-converting enzyme gene and angiotensinogen gene loci in relation to blood pressure. Hypertension 28 (1996) 1070-1075
27. Rantala A.O., Kauma H., Lilja M., et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 245 (1999) 163-174
28. Kullo I.J., Gau G.T., and Tajik A.J. Novel risk factors for atherosclerosis. Mayo Clin Proc 75 (2000) 369-380
29. Brown M., Schiffman G., and Rittenberg M.B. Subpopulations of antibodies to phosphocholine in human serum. J Immunol 132 (1984) 1323-1328
30. Burke G.L., Evans G.W., Riley W.A., et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) study. Stroke 26 (1995) 386-391
31. Frostegård J., Ulfgren A.K., Nyberg P., et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145 (1999) 33-43
32. Schonbeck U., Sukhova G.K., Gerdes N., et al. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol 161 (2002) 499-506
33. Inoue T., Komoda H., Nonaka M., et al. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 124 (2008) 319-325
34. Avramakis G., Papadimitraki E., Papakonstandinou D., et al. Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. Platelets 18 (2007) 16-23
35. Prokesova L., Lodinova-Zadnikova R., Zizka J., et al. Cytokine levels in healthy and allergic mothers and their children during the first year of life. Pediatr Allergy Immunol 17 (2006) 175-183
36. Wetzel G.D. Interleukin 5 regulation of peritoneal Ly-1 B lymphocyte proliferation, differentiation and autoantibody secretion. Eur J Immunol 19 (1989) 1701-1707
37. Sakiyama T., Ikuta K., Nisitani S., et al. Requirement of IL-5 for induction of autoimmune hemolytic anemia in anti-red blood cell autoantibody transgenic mice. Int Immunol 11 (1999) 995-1000
38. Moon B.G., Takaki S., Miyake K., et al. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production. J Immunol 172 (2004) 6020-6029
39. Berland R., and Wortis H.H. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 20 (2002) 253-300
40. Tominaga A., Takaki S., Koyama N., et al. Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production. J Exp Med 173 (1991) 429-437
41. Yoshida T., Ikuta K., Sugaya H., et al. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity 4 (1996) 483-494
42. Nagasawa M., Ohshiba A., and Yata J. Effect of recombinant interleukin 5 on the generation of cytotoxic T cells (CTL). Cell Immunol 133 (1991) 317-326
43. Sakuishi K., Oki S., Araki M., et al. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 179 (2007) 3452-3462
44. Leckie M.J. Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med 2 (2003) 245-259